Recent headlines surrounding Agenus stock focus heavily on clinical pipeline updates for its flagship immuno-oncology combination therapies, strategic royalty financing agreements designed to extend its cash runway, and updates regarding Nasdaq compliance. Financial media coverage also tracks capital restructuring efforts, subsidiary developments with MiNK Therapeutics, and upcoming medical congress data presentations.